Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.

ClinicalTrials.gov Identifier: NCT05222529

Novartis Reference Number: CQVM149C2201

Last Update: Nov 18, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.

Condition 
Asthma
Phase 
Phase 2
Overall status 
Recruiting
Start date 
Aug 29, 2022
Completion date 
Feb 12, 2024
Gender 
All
Age(s)
6 Years - 11 Years (Child)

Interventions

Drug
Glycopyrronium bromide 25ug
25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Drug
Placebo
Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Drug
Glycopyrronium bromide 12.5ug
12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of asthma for at least 6 months
Signed informed consent by parent(s)/legal guardian(s) and assent by the pediatric patient (depending on local requirements)
Patient on stable dose of inhaled low-to-medium dose ICS with one additional controller for at least 4 weeks prior to randomization
Pre-Bronchodilator FEV1 ≥60% to ≤90% of predicted normal at beginning of Run-in and randomization
FEV1 reversibility, done using up to 4 puffs of SABA (up to 400μg salbutamol or 360μg albuterol) at Run-in visit (Visit 20): increase > and/or = 12% (performed according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 2019 guidelines). All patients must perform a reversibility test at start of Run-in. If reversibility is not demonstrated at Run-in, it may be repeated once on the same day. If reversibility is still not demonstrated after repeated assessment patients must be screen failed
Demonstrated acceptable inhaler use technique for Breezhaler and Diskus/Accuhaler prior to randomization, and able to complete spirometry procedures prior to randomization
A parent/legal guardian must be designated to complete all e-Diary entries and attend all clinic visits with the patient
Parents/legal guardian must be willing and able to assist the child with the procedures outlined in the protocol, e.g. compliance with study medication, completion of electronic patient diary
Female patients of child-bearing potential, who might become sexually active, must be informed of the need to prevent pregnancy during the study using effective contraceptive methods. The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen.

Exclusion Criteria:

Systemic corticosteroid use for any reason within 3 months of Run-in
Patients on low to medium mono ICS alone
Patients requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Screening (Visit 1) and/or in the four weeks prior to the Run-in visit
Patients who have had an asthma attack/exacerbation requiring a) systemic corticosteroids (SCS) or b) hospitalization or c) emergency room visit, within 3 months prior to Screening (Visit 1), or more than 3 separate exacerbations in the 12 months preceding the Screening visit
Patients with a known narrow-angle glaucoma, bladder dysfunction, bladder outlet obstruction or any other conditions where anticholinergic treatment is contraindicated prior to Screening (Visit 1)
Patients with a history of long QT syndrome or whose corrected QT interval (QTc) measured at start of Run-in and confirmed at Baseline (prior to randomization) (Fridericia method) is prolonged (> 450 msec for boys and girls) and confirmed by a central assessor (these patients should not be rescreened)
Suspected or documented active infections (bacterial, viral, fungal, mycobacterial or other, including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease) of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 6 weeks of Screening (Visit 1)
History of Type I diabetes or uncontrolled Type II diabetes
Patients who are sexually active at screening
Hemoglobin levels outside normal ranges at Run-in (Visit 20)
Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if they become sexually active during study participation, do not agree to the use of contraception as defined in the inclusion criteria.

Additional protocol-defined inclusion / exclusion criteria may apply.

Study Locations

Bulgaria
Novartis Investigative Site
Recruiting
Sevlievo, 5400
-
Bulgaria
Novartis Investigative Site
Recruiting
Sofia, 1309
-
Bulgaria
Hungary
Novartis Investigative Site
Recruiting
Kaposvar, 7400
-
Hungary
Novartis Investigative Site
Recruiting
Nagykanizsa, 8800
-
Hungary
Novartis Investigative Site
Recruiting
Szigetvar, 7900
-
Hungary
Poland
Novartis Investigative Site
Recruiting
Lodz, 90-329
Lodzkie
Poland
Novartis Investigative Site
Recruiting
Tarnow, 33-100
-
Poland
Spain
Novartis Investigative Site
Recruiting
Esplugues de Llobregat, 08950
Barcelona
Spain
Novartis Investigative Site
Recruiting
Sabadell, 08208
Barcelona
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08035
Catalunya
Spain
Novartis Investigative Site
Recruiting
Merida, 06800
Extremadura
Spain

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]